drugset / Trial / NCT07538336

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336

Phase 2 Not yet recruiting 40 enrolled University of California, San Francisco
RandomizedSequentialDouble-blindTreatment

Summary

This study is testing a medication called emapalumab to see if it can help people who have had a lung transplant and are experiencing a sudden drop in lung function, called acute lung allograft dysfunction (ALAD). ALAD is a serious condition that can happen after a lung transplant and can lead to worsening breathing and other complications. Right now, there is no approved treatment for ALAD. The main goal is to see if lung function improves, meaning it returns close to your usual (baseline) level within 90 days.

Timeline

Start
2026-11-02
Primary completion
2028-11-01
Completion
2028-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Emapalumab Monoclonal antibody Intravenous

Indications

No indication recorded.